IMO an easy comparison to RAP could be made to show just how undervalued we are, RAP sits at $130mil cap with barely any revenue and we sit at $60mil cap with millions more in revenue that is growing.
UCM covers the whole mobile coughing/asthma/COPD market in their own way too as just one portion of the business.
coronavirus is a great way for the company to have the spotlight on it, but as Rob states, this is actually only a fraction of the market we can serve
“Our products address diseases responsible for 75 per cent of the world’s mortalities: heart failure, sepsis, hypertension, asthma and [chronic obstructive pulmonary disease],” Professor Rob Phillips says.“This is stuff that the world spends billions on.”
Add to My Watchlist
What is My Watchlist?
